HCXY Q1 2026 Earnings Call Summary

Hercules Capital Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Investment Income: $141.5 million, a record high, up 18.4% year-over-year.
Net Investment Income (NII): $88.1 million or $0.48 per share, up 13.8% year-over-year.
Core Yield: 12.2%, slightly down from 12.5% in the previous quarter.
Return on Equity (ROE): 16.9%, an increase from 16.4% in Q4 2025.
Net Asset Value (NAV) per Share: $11.90, down 1.9% from Q4 2025.
GAAP Leverage: Increased to 115.4%, up from 104.4% in Q4 2025.
Liquidity: Over $1 billion across the platform, with $454.5 million in the BDC.

2. Strategic Updates and Business Highlights

Record Originations: $1.81 billion in new debt and equity commitments, with gross fundings exceeding $706 million.
Portfolio Composition: 50% in life sciences and 50% in technology, with a focus on diversification.
Credit Quality: Stable with a weighted average internal credit rating of 2.11; only 0.9% of loans rated 4 or 5.
M&A Activity: Four new M&A events in the portfolio, indicating strong exit opportunities.
Leadership Changes: Seth Meyer transitioning to President, with Andrew Olson returning as CFO.

3. Forward Guidance and Outlook

Q2 Expectations: Anticipated core yield to remain between 12% to 12.5%.
Prepayment Guidance: Expected to increase significantly to $350 million to $500 million in Q2, driven by M&A.
Investment Strategy: Continued focus on disciplined underwriting and maintaining a conservative balance sheet amid market volatility.

4. Bad News, Challenges, or Points of Concern

NAV Decline: Decreased by 1.9% due to unrealized depreciation from market volatility.
Market Volatility: Ongoing concerns related to AI disruption and geopolitical tensions affecting the broader market.
Increased Operating Expenses: Rising costs associated with record new originations, which may pressure margins.
Credit Monitoring: Enhanced scrutiny of portfolio due to market conditions, though credit quality remains stable.

5. Notable Q&A Insights

Portfolio Performance: Management emphasized the strength of their diversified portfolio, particularly in life sciences, which is expected to benefit from ongoing FDA developments.
Prepayment Impact: Increased prepayments viewed positively, allowing for capital redeployment into high-quality opportunities.
Structural Changes in Underwriting: Emphasis on tighter structures and covenants over chasing yield, reflecting a cautious approach in the current market.
AI Impact: While AI is a concern, management noted that most M&A activity in their portfolio is not directly driven by AI trends.

Overall, Hercules Capital reported a strong Q1 2026 with record financial metrics and a robust outlook, despite facing challenges from market volatility and declining NAV. The strategic focus remains on disciplined underwriting and capitalizing on favorable market conditions.

HCXY — Hercules Capital, Inc.